Sanofi to Invest up to $60 Million in Gyroscope Therapeutics

UK-based Gyroscope Therapeutics announced Nov. 8 that France’s Sanofi had committed to invest up to $60 million in equity in Gyroscope. Sanofi will invest $40 million initially, at a premium to Gyroscope’s prior Series C financing, and the remaining $20 million will be contingent on a future qualifying investment round and subject to certain closing conditions. Under the agreement, a …

US FDA Clears IND for 4DMT’s Wet AMD Gene Therapy Candidate

4D Molecular Therapeutics announced Oct. 6 that the US FDA had cleared the investigational new drug application (IND) for 4D-150 for wet age-related macular degeneration (wet AMD). 4D-150 is a dual-transgene intravitreal gene therapy that targets four distinct angiogenic factors, which 4DMT says has the potential for broad and durable efficacy after a single intravitreal administration in patients with wet …

Adverum Presents Data Showing Gene Therapy Maintained Efficacy, Durability, Safety in Wet AMD Patients

Adverum Biotechnologies announced new long-term data from the OPTIC clinical trial of ADVM-022 single, in-office intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). Safety and efficacy data from patients followed through 2 years post injection are being presented at the Retina Society’s 54th Annual Scientific Meeting in Chicago. The presentation is available on …

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

Eyevensys has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology.  Terms of the deal were not diclosed. Eyevensys has developed a non-viral gene therapy ocular drug delivery platform with a proprietary Electrotransfection System designed to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle and sustainably treat major eye diseases. …

Novartis Acquires Arctos Medical, Expanding Optogenetic Gene Therapy Pipeline

Swiss company Novartis announced Sept. 21 that it had acquired Arctos Medical, developer of a potential optogenetic AAV gene therapy for inherited retinal disease. Financial details were not disclosed. The move comes a year after Novartis paid $150 million up front and a potential $130 million in milestone payments in September 2020 for Vedere Bio of Cambridge, Massachusetts.

AbbVie Makes Large Investment in Regenxbio’s Gene Therapy for Retinal Diseases

AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate …

MeiraGTx Announces Data at EURETINA 2021 Demonstrating Reversal of Disease Progression Following Treatment With AAV5-RPGR in XLRP

MeiraGTx Holdings announced new data from subjects treated in the phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal function assessed 12 months following treatment with AAV5-RPGR is compared with retinal function in these same subjects up to …

GenSight Says RESTORE Study of Lumevoq Shows Sustained Efficacy 3 Years After Unilateral Treatment

GenSight Biologics reported Aug. 31 that the Journal of Neuro-Ophthalmology (JNO) had published results from a long-term follow-up study of the gene therapy candidate Lumevoq that show sustained, bilateral treatment effect three years after a unilateral injection.The RESTORE study followed 61 patients with Leber hereditary optic neuropathy (LHON) due to a mutated ND4 mitochondrial gene.Paris-based GenSight said subjects in the …